Segment Information (Narrative) (Details) (USD $)	6 Months Ended
Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010
Segment Information
Number of other generic drugs not detailed	60
Maximum percentage revenue of other products compared to generic products.	3.00%	3.00%
Payment on agreement termination			$ 2,000,000
Royalty Revenue	4,300,000
Gain on sale of product rights		$ 5,921,000

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration